Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 3/20 | 0.48 |
| ▸ | SLC22A12 | Q96S37 | 4/20 | 0.48 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 5/20 | 0.44 |
| ▸ | HTR6 | P50406 | 2/20 | 0.43 |
| ▸ | ABCC9 | O60706 | 2/20 | 0.43 |
| ▸ | ABCC8 | Q09428 | 2/20 | 0.43 |
| ▸ | KCNJ11 | Q14654 | 2/20 | 0.43 |
| ▸ | KCNJ8 | Q15842 | 2/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22954102 | 0.83 | HTR6 (0.61) | NAMPTSLC22A12CNR2HSD11B1HTR6 | |
| SCHEMBL13728197 | 0.77 | NAMPT (0.49) | NAMPTCNR2HSD11B1HTR6ABCC9 | |
| SCHEMBL27955163 | 0.77 | ABCC9 (0.54) | NAMPTSLC22A12CNR2HTR6ABCC9 | |
| SCHEMBL161866 | 0.77 | CACNA1H (0.53) | NAMPTSLC22A12HSD11B1 | |
| SCHEMBL6039108 | 0.76 | SLC22A12 (0.48) | SLC22A12CNR2HTR6 | |
| SCHEMBL26286122 | 0.75 | HSD11B1 (0.51) | SLC22A12CNR2HSD11B1ABCC9ABCC8 | |
| SCHEMBL163742 | 0.73 | NAMPT (0.49) | NAMPTHTR6ABCC9ABCC8KCNJ11 | |
| SCHEMBL10646541 | 0.73 | SLC22A12 (0.48) | SLC22A12CNR2HTR6 | |
| SCHEMBL4074736 | 0.72 | SLC22A12 (0.49) | NAMPTSLC22A12HTR6 | |
| SCHEMBL11052553 | 0.71 | PARP15 (0.48) | NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103717574-B | Novel compounds and compositions for the inhibition of nampt | 福马TM有限责任公司 | 2017-02-22 | — | — | CN | disclosed |
| US-9169209-B2 | Compounds and compositions for the inhibition of NAMPT | FORMA TM, LLC (US) | 2015-10-27 | — | — | US | disclosed |
| US-9169209-B2 | Compounds and compositions for the inhibition of NAMPT | FORMA TM, LLC (US) | 2015-10-27 | — | — | US | disclosed |
| US-20140275057-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | Valo Health, LLC | 2014-09-18 | — | — | US | disclosed |
| US-20140275057-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | Valo Health, LLC | 2014-09-18 | — | — | US | disclosed |
| CN-103717574-A | Novel compounds and compositions for the inhibition of nampt | FORMA TM LLC | 2014-04-09 | — | — | CN | disclosed |
| WO-2012150952-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | FORMA TM, LLC (US) | 2012-11-08 | — | — | WO | disclosed |
| WO-2012150952-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | FORMA TM, LLC (US) | 2012-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275057-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NAPRT | NAMPT 1/4885SLC22A12 455/4885CNR2 1365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.